PharmaJet collaborates with Genexine to commercialize DNA Vaccines

Maker of innovative, needle-free injection technology,  PharmaJet asserted venturing into a global license agreement with  Genexine, for the development and commercialization of DNA vaccines for human applications utilizing the PharmaJet needle-free injection systems.

As per the terms of the agreement, Genexine will use both the PharmaJet Stratis and Tropis devices in their Phase 1 and IIa human clinical studies. Immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies.  DNA vaccines can be used as targeted “therapeutic vaccines” to induce an immune response which can detect and destroy infectious diseases and potentially cancer. Genexine’s product pipeline, focused on innovative immunotherapeutics and next generation novel long-acting biologics, includes a vaccine for human papilloma virus (HPV) type 16 and 18 associated cervical intraepithelial neoplasia (CIN),

Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc said “We are pleased to be part of the upcoming clinical trials of these DNA vaccines. Our needle-free technology features a precise and consistent method of delivery, which helps to maximize target gene expression in the human body.”